Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Virogenics Inc
Profile last edited on: 8/1/17      CAGE: 476X3      UEI: UFJ8JM4CXU22

Business Identifier: Immunology-based treatment of disease
Year Founded
2003
First Award
2003
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4050 Sorrento Valley Boulevard
San Diego, CA 92121
   (858) 450-2561
   N/A
   N/A
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Virogenics Inc is a biotechnology company developing immunology-based treatments for disease. The principals at the company have backgrounds in cellular neurobiology and vaccine development.

Extent of SBIR involvement

User Avatar
Phase I Awards
7
Phase II Awards
6
Conversion Rate
85.71%
Phase I Dollars
$1,823,908
Phase II Dollars
$8,534,927
Total Awarded
$10,358,835

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 2 NIH $5,011,558
Project Title: Modulation of the Innate Immune System by Fisetin for the Treatment of AD
2014 2 NIH $600,000
Project Title: Sirna Modulation of the Immune Response
2012 2 NIH $2,649,280
Project Title: FIV Vectors for the Treatment of Hemophilia A
2009 2 NIH $599,314
Project Title: A Novel Immune Modulator/ Adjuvant For Hiv Vaccines
2007 1 NIH $149,881
Project Title: Hemophilia A: Intrathymic Delivery for Tolerance and Longterm Expression of FVIII

Key People / Management

  William C Raschke -- President

  Pamela Anne Maher

  Girija Muralidhar -- Director of Vaccines Program

  William C Raschke

  Carol-Gay Yates -- Director of Preclinical Studies

Company News

There are no news available.